111 (YI) Stock Price, News & Analysis

Company Overview

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

Key Stats

• Today's Range: $8.07 to $8.35
• 50-Day Range: $6.15 to $8.53
• 52-Week Range: $4.15 to $12.90
• Volume: 7,183 shs
• Average Volume: 24,221 shs
• Market Capitalization: $69.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

111 Stock Analysis - MarketRank™

111 scored higher than 14% of companies evaluated by MarketBeat, and ranked 886th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for 111.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of 111 is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 111 is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of 111 has been sold short.

Short Interest Ratio / Days to Cover

111 has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 111 has recently decreased by 1.79%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

111 does not currently pay a dividend.

Dividend Growth

111 does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.11% of the float of 111 has been sold short.

Short Interest Ratio / Days to Cover

111 has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 111 has recently decreased by 1.79%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.27

News Sentiment

111 has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for 111 this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, 111 insiders have not sold or bought any company stock.

Percentage Held by Insiders

43.90% of the stock of 111 is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 21.32% of the stock of 111 is held by institutions.

YI Stock Analysis - Frequently Asked Questions

How have YI shares performed this year?

111's stock was trading at $6.23 at the beginning of the year. Since then, YI shares have increased by 29.5% and is now trading at $8.07.
View the best growth stocks for 2025 here.

How were 111's earnings last quarter?

111, Inc. (NASDAQ:YI) released its earnings results on Thursday, March, 20th. The company reported ($0.04) earnings per share for the quarter. The business earned $527.14 million during the quarter.
Read the conference call transcript.

When did 111's stock split?

111 shares reverse split on the morning of Friday, January 24th 2025. The 1-10 reverse split was announced on Wednesday, January 8th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 23rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did 111 IPO?

111 (YI) raised $140 million in an initial public offering on Wednesday, September 12th 2018. The company issued 9,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup and CICC acted as the underwriters for the IPO.

Who are 111's major shareholders?

Top institutional investors of 111 include Connor Clark & Lunn Investment Management Ltd. (0.13%) and Deuterium Capital Management LLC (0.12%).

How do I buy shares of 111?

Shares of YI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 111 own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 111 investors own include NVIDIA (NVDA), Teladoc Health (TDOC), Innovative Industrial Properties (IIPR), Magnite (MGNI), Roku (ROKU), Twilio (TWLO).

Company Calendar

• Last Earnings: 3/20/2025
• Today: 6/10/2025
• Next Earnings (Estimated): 6/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Drug stores & proprietary stores
• Sub-Industry: Retail
• Current Symbol: NASDAQ:YI
• CIK: 1738906
• Web: www.111.com.cn
• Phone: 862120536666
• Fax: N/A
• Employees: 2,110
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.07 million
• Net Margins: -1.75%
• Pretax Margin: -1.48%
• Return on Equity: N/A
• Return on Assets: -8.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.09
• Quick Ratio: 0.51

Sales & Book Value

• Annual Sales: $14.40 billion
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($9.79) per share
• Price / Book: -0.85

Miscellaneous

• Outstanding Shares: 8,644,000
• Free Float: 4,798,000
• Market Cap: $71.53 million
• Optionable: Optionable
• Beta: 0.47